<DOC>
	<DOCNO>NCT01980199</DOCNO>
	<brief_summary>This study design determine efficacy Fexinidazole oral treatment Visceral Leishmanisasis sudanese adult patient . The result proof concept study allow make decision whether proceed clinical development Fexinidazole visceral leishmaniasis .</brief_summary>
	<brief_title>Trial Determine Efficacy Fexinidazole Visceral Leihmaniasis Patients Sudan</brief_title>
	<detailed_description>Visceral Leishmaniasis ( VL ) neglect disease fatal left untreated . Until recently first line treatment East Africa 30 day Sodium Stibogluconate cardiotoxic . Since 2010 WHO recommend Sodium Stibogluconate Paromomycin 17 day shorter treatment remain toxicity associate drug . The second line treatment Ambisome give 6-10 intravenous infusion , whilst good safety profile VL regimens expensive . So urgent need short course oral treatment VL particularly East African region . Fexinidazole 2 substitute 5-nitroimidazole formulated oral administration . Fexinidazole metabolites demonstrated potent activity againts L. donovani intracellular amastigotes vitro vivo visceral leishmaniasis mouse model . The dose select study ( 1800 mg/1200 mg 4/6 day ) base dose select phase II trial Human African Trypasonomiasis . It albeit well tolerated one dose level maximum tolerate dose level establish phase I . The trial design analyse accord sequential method know triangular test , use day 28 data . This sequential design allow repeat interim analysis ( every 10 patient ) . The null hypothesis proportion cure less equal 75 % . The primary endpoint initial cure day 28 . The primary population interim analyse interim decision make per protocol population.In final analysis cumulative patient data , Intention Treat Per Protocol Population analyse conduct . The conventional 6 month ( day 210 ) follow outcome still important secondary endpointfor final decision whether proceed clinical development Fexinidazole VL .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<criteria>Patients clinical sign symptom primary VL ( fever least 2 week , splenomegaly ) diagnosis confirm visualization parasite tissue sample ( lymph node , bone marrow ) microscopy . Patients age 15 60 year ( inclusive ) able comply protocol . Patients write informed consent sign patient ( age 18 year ) parent ( ) legal guardian patient 18 year age together patient assent . HIV negative status Patients previously diagnose VL receive antileishmanial treatment ( ie relapse ) Patients BMI &lt; 16 kg/m2 Patients contraindication ( know hypersensitivity ) imidazole ( e.g . ketaconazole ) Patients suffer concomitant severe underlying disease ( cardiac , renal , hepatic ) include hepatitis B , para kalaazar dermal leishmaniasis tuberculosis Patient clinically significant ECG finding QTcF≥ 450 msec 2 successive ECGs Major surgical intervention 4 week prior enrollment . Patients pregnant lactate . Female patient child bear age agree use acceptable method contraception Patients haemoglobin &lt; 5g/dl . Patients platelets &lt; 40,000/mm³ . Patients liver function ( ALT AST ) test 2 time upper limit normal range . Patients serum creatinine normal range age gender . Patients serum potassium ( K+ ) normal range Patients Bilirubin 1.5 time upper limit normal range</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>visceral leishmaniasis</keyword>
	<keyword>fexinidazole</keyword>
	<keyword>adult</keyword>
	<keyword>proof concept</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>